NKX2-2 is a homeodomain-containing transcriptional regulator essential for endocrine pancreatic development and central nervous system patterning 1. As a transcriptional activator, NKX2-2 controls insulin-producing β-cell specification 2, where it functions alongside developmental transcription factors to reprogram fibroblasts toward β-cell fate, resulting in glucose-responsive insulin secretion 2. In the CNS, NKX2-2 marks oligodendrocyte progenitor cells (OPCs) and V3 spinal interneurons during neural development 345. NKX2-2 expression emerges around day 18 of in vitro oligodendrocyte differentiation from pluripotent stem cells, preceding mature oligodendrocyte formation 3. In spinal cord development, NKX2-2 serves as a V3-specific marker enabling enrichment of interneuron progenitors to ~95% purity 5. Pathologically, loss-of-function NKX2-2 mutations cause neonatal diabetes 1, while aberrant expression associates with pancreatic cancer subtypes; ADEX tumors display NKX2-2 upregulation alongside endocrine differentiation markers 6. NKX2-2 is also expressed in certain neurocristic tumors and oligodendroglial neoplasms 78, suggesting variable oncogenic/tumor suppressor roles depending on cellular context.